Health Care [ 5/12 ] | Biotechnology [ 19/75 ]
NASDAQ | Common Stock
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer.
The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University.
The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 13, 26 | -2.98 Decreased by -610.05% | -5.52 Increased by +45.95% |
| Nov 12, 25 | -3.72 Decreased by -830.00% | -0.30 Decreased by -1.14 K% |
| Aug 14, 25 | -4.46 Decreased by -869.57% | -0.31 Decreased by -1.34 K% |
| May 12, 25 | -0.29 Decreased by -3.57% | -0.36 Increased by +19.44% |
| Mar 19, 25 | -0.42 Increased by +10.64% | -0.35 Decreased by -20.00% |
| Nov 7, 24 | -0.40 Increased by +6.98% | -0.40 Decreased by -1.27% |
| Aug 13, 24 | -0.46 Increased by +4.17% | -0.48 Increased by +4.17% |
| May 14, 24 | -0.28 Increased by +37.78% | -0.51 Increased by +45.10% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 2.50 M Decreased by -89.62% | -6.63 M Increased by +58.39% | Decreased by -265.24% Decreased by -300.99% |
| Sep 30, 25 | 2.17 M Increased by +90.10% | -7.14 M Increased by +52.93% | Decreased by -329.37% Increased by +75.24% |
| Jun 30, 25 | 1.80 M Increased by +41.49% | -8.56 M Increased by +59.61% | Decreased by -474.56% Increased by +71.45% |
| Mar 31, 25 | 1.22 M Decreased by -76.83% | -11.04 M Decreased by -2.12% | Decreased by -903.44% Decreased by -340.73% |
| Dec 31, 24 | 24.09 M Increased by +1.05 K% | -15.94 M Increased by +10.99% | Decreased by -66.15% Increased by +92.28% |
| Sep 30, 24 | 1.14 M Decreased by -54.87% | -15.18 M Increased by +6.65% | Decreased by -1.33 K% Decreased by -106.83% |
| Jun 30, 24 | 1.27 M Decreased by -11.03% | -21.20 M Decreased by -17.38% | Decreased by -1.66 K% Decreased by -31.92% |
| Mar 31, 24 | 5.27 M Increased by +188.83% | -10.81 M Increased by +36.33% | Decreased by -204.99% Increased by +77.96% |